SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is currently trending as investors debate whether the recent price decline represents an oversold opportunity or a long-term exhaustion of the project's potential. While some community members are actively dollar-cost averaging to lower their cost basis, others are voicing frustration over the persistent disconnect between the network's ongoing enterprise utility and the token's stagnant market performance.

Ardelyx, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. Its products include IBSRELA and XPHOZAH. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is attracting significant market attention following a robust Q1 earnings report, continued volume growth for its key products, and ongoing speculation regarding potential strategic acquisitions by Zydus Lifesciences. Investors are closely monitoring the stock as it gains momentum, balancing positive commercial execution with the anticipation of a definitive court ruling regarding the company's long-standing Medicare reimbursement dispute.

Sezzle, Inc. engages in the operation of a digital payment platform that enables bank-to-bank transfer of money between consumers and businesses. The company was founded by Charlie G. Youakim, Killian Brackey and Paul V. Paradis on January 4, 2016 and is headquartered in Minneapolis, MN.

Sezzle Inc.

Sezzle is seeing intense community debate as investors weigh the stock's long-term fintech fundamentals against recent volatility and aggressive short-selling activity. While some traders are focused on potential short squeezes and high-growth metrics, others are closely monitoring board governance changes and broader market macro-headwinds.

BTQ Technologies Corp. engages in the business of post-quantum encryption. Its products include: QCIM, QSSN, OSS, QPoW, QRiNG. The company was founded by Nicolas Roussy Newton on Novemeber 23, 1983 and is headquartered in Vancouver, Canada.

BTQ Technologies Corp

BTQ is gaining significant community traction as investors track its post-quantum cybersecurity developments, including a new hardware hub in New York and strategic engineering hires aimed at accelerating commercialization. While some are debating the volatility of its retail-heavy trading patterns and the impact of internal management drama, the consensus focus remains on the urgent industry need for quantum-resistant infrastructure and the potential for long-term growth through future commercial partnerships.

BRC Group Holdings, Inc. engages in the provision of financial services and solutions to the capital raising and financial advisory needs of public and private firms. It operates through the following segments: Capital Markets, Wealth Management, Lingo, magicJack, Marconi Wireless, United Online (UOL), and Consumer Products. The Capital Markets segment provides investment banking, corporate finance, research, wealth management, and sales and trading services to corporate, institutional, and high net worth clients. The Wealth Management segment offers retail brokerage, investment management, and insurance, and tax preparation services. The Lingo segment offers a global cloud or unified communications and managed service provider to Enterprise and Small to Medium Businesses in the United States. The magicJack VoIP segment is a non-interconnected Voice-over-IP (VoIP) cloud-based communications service provider that offers related devices and subscription services within the United States and Canada. The Marcon segment is a mobile virtual network operator that provides mobile phone voice, text, and data services and devices using the Credo Mobile brand. The United Online segment is an Internet access provider that offers dial-up and digital subscriber line services under the NetZero and Juno brands across the United States. The Consumer Products segment generates revenue through sales of laptop and computer accessories. The company was founded in 1973 and is headquartered in Los Angeles, CA.

BRC Group Holdings Inc.

B. Riley Financial Inc

B. Riley Financial is trending as investors focus on its significant stakes in high-growth companies like SpaceX and Babcock & Wilcox, fueling optimism that these positions will catalyze a valuation rerate and help the firm address its debt obligations. Community discussion remains polarized, with many retail participants expressing frustration over management's transparency and the stock's sluggish price action, while others highlight the potential for a gamma squeeze and long-term upside driven by the company's capital markets activity and upcoming index inclusion.

Flutter Entertainment Plc engages in the business of online betting and gaming. It operates through the following segments: UK and Ireland, Australia, International, and US. The UK and Ireland segment includes the operations of Sky Betting and Gaming, Paddy Power, Betfair, and tombola. The Australia segment focuses on sports betting services provided to Australian customers online. The International segment relates to poker, casino, rummy, lottery, and sports betting. The US segment includes sports betting, daily fantasy sports, and gaming services. The company was founded in 1988 and is headquartered in New York, NY.

Flutter Entertainment Plc

Flutter Entertainment is currently under significant market pressure following a series of negative analyst outlooks and leadership changes at its FanDuel division, which have compounded ongoing investor concerns regarding U.S. betting growth and intensifying competition. Despite these headwinds, the community is actively debating the company's valuation as a potential long-term value play, focusing heavily on how it will navigate regulatory uncertainty and the rise of prediction market platforms.

Lionsgate Studios Corp. operates as a standalone, pure-play content company focused on creating, producing, and distributing premium entertainment across multiple formats and platforms. It operates through the following segments: Motion Picture and Television Production. The Motion Picture segment includes the development and production of feature films, acquisition of North American and worldwide distribution rights, North American theatrical, home entertainment, and television distribution of produced and acquired films, as well as the worldwide licensing of distribution rights. The Television Production segment covers the development, production, and worldwide distribution of television content, including series, television movies, mini-series, and non-fiction programming. The company was founded on January 13, 2024 and is headquartered in Vancouver, Canada.

Lionsgate Studios Corp. - Ordinary Shares - New

Lionsgate Studios Corp.

Lionsgate Studios is currently trending as a potential acquisition target following reports of takeover interest from Legendary Entertainment, fueling community speculation about a competitive bidding war. Investors are closely monitoring the company's strong content library and upcoming theatrical releases as catalysts that could drive a premium valuation in the current media consolidation landscape.

Horizon Quantum Holdings Ltd. engages in the development of software tools. The company is headquartered in Singapore.

Horizon Quantum Holdings Ltd. - Ordinary Shares - Class A

Horizon Quantum (HQ) is seeing intense volatility and massive volume spikes as traders track its role as a potential 'Microsoft of quantum computing' software, bolstered by strategic investments from industry leaders like IonQ and Dell. The community is heavily focused on the stock's low public float and recent de-SPAC status, fueling speculation about a potential short squeeze even as some investors express caution regarding the company's valuation and long-term patent moat.

Chip

The community is actively debating the long-term utility of the USD.AI ecosystem, specifically focusing on its GPU-backed lending model and governance potential versus claims of insider selling and high volatility. Investors remain split between those bullish on the protocol's role in the AI infrastructure boom and those concerned about circulating supply and persistent downward price action.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending as the community debates the commercial launch of NEREUS for motion sickness and speculates on potential acquisition interest from major pharmaceutical players. Investors remain focused on the company's GLP-1 adjunct pipeline and upcoming clinical study results, even as sentiment is tempered by frustration over price volatility and management's aggressive regulatory strategy.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SYRE Completes Enrollment in SKYWAY Basket Study on SPY072, Stock Up

Spyre Therapeutics gains after completing enrollment in all SKYWAY phase II sub-studies evaluating SPY072 across three rheumatic diseases.

Upcoming Phase 2 Readouts Could Redefine These Biotech Stocks

Upcoming Phase 2 Readouts Could Redefine These Biotech Stocks $NTHI, $ORKA, $ABVX, $CGEM, $SYRE, $APGE

Spyre Therapeutics (NASDAQ:SYRE) Price Target Raised to $97.00 at Citigroup

Citigroup upped their target price on shares of Spyre Therapeutics from $64.00 to $97.00 and gave the company a "buy" rating in a research note on Wednesday...

Insider Selling: Spyre Therapeutics (NASDAQ:SYRE) CEO Sells 15,000 Shares of Stock

Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) CEO Cameron Turtle sold 15,000 shares of the company's stock in a transaction dated Friday, May 1st. The stock was sold at an average price of...

Spyre Therapeutics (NASDAQ:SYRE) Insider Sells $5,600,809.50 in Stock

Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) insider Sheldon Sloan sold 78,333 shares of Spyre Therapeutics stock in a transaction on Friday, May 1st. The shares were sold at an average...

Insider Selling: Spyre Therapeutics (NASDAQ:SYRE) CFO Sells 12,500 Shares of Stock

Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) CFO Scott Burrows sold 12,500 shares of Spyre Therapeutics stock in a transaction on Friday, May 1st. The shares were sold at an average price...

Spyre Therapeutics (NASDAQ:SYRE) Trading Down 6.3%  - Here's What Happened

Spyre Therapeutics (NASDAQ:SYRE) Trading Down 6.3% - Here's Why...

Pictet Asset Management Holding SA Cuts Stake in Spyre Therapeutics, Inc. $SYRE

Pictet Asset Management Holding SA cut its holdings in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 11.8% during the 4th quarter, according to the company in its most recent Form...

Spyre Therapeutics (NASDAQ:SYRE) Reaches New 1-Year High - Here's What Happened

Spyre Therapeutics (NASDAQ:SYRE) Sets New 1-Year High - Still a Buy...

Universal Beteiligungs und Servicegesellschaft mbH Raises Stake in Spyre Therapeutics, Inc. $SYRE

Universal Beteiligungs und Servicegesellschaft mbH boosted its stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 55.0% in the fourth quarter, according to the company in its most...

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe on December 16, 2013 and is headquartered in Waltham, MA.

Spyre Therapeutics Inc.

SYRE Stock Marks Best Session In About 3 Years — Here’s Why 

Equity

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

SYRESpyre Therapeutics Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SYRE News